Africa has the highest number of newborn deaths of any continent in the world. Roughly 1.16 million infants die each year in Africa, 51 percent of the world’s total. We estimate that our NeoLife Ventilator could prevent approximately 27 percent of these deaths. We are starting by targeting the East Africa region where 302,859 children under the age of 5 die each year, many from preventable respiratory-related causes.
In the East African Community, we estimate that our NeoLife Ventilator has the potential to prevent the deaths of 33,627 newborns each year who suffer from respiratory related issues. Uganda holds 32 percent of the newborn respiratory deaths in the East African Community. In this country alone, that potentially makes 10,756 newborns who will have the chance to live with access to this machine. After getting our start in Uganda we will spread throughout the region.
It is important to note that there are hundreds of births that do not happen in the hospitals. By providing a cost-friendly but high-quality product in hospitals and health centers, we hope to create community awareness of what resources are available and improve the local confidence in the health care system, thus motivating more mothers to give birth in a medical setting.
We are completing necessary tests to submit a 510K application with the FDA (expected completion: August 2017). In the meantime, we will begin selling care packages in East Africa (i.e. Uganda), establishing connections to bigger hospitals, and strengthening our relationships in the region.
We will launch NeoLife Gen 2 and begin selling the device to government, PNFP (NGO), and private Hospitals in Uganda. We will train doctors operate the device and provid continued support and training through partnerships with American hospitals and videos on our app.
After successfully proving the impact of our model, we will expand throughout all of the East African community—including Rwanda, Kenya, and Tanzania—and beyond.